TICKERNERD
Menu
TWSTTWSTHealthcare · Diagnostics & Research

TWST Stock Forecast: Twist Bioscience Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$119
−5.36% on the day

The 11 Wall Street analysts covering Twist Bioscience Corp. hold a median 12-month price target of $115 — -3.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$7.4B
Ticker Nerd rank
63 / 100
Median analyst target
$115
Analysts covering
11
Total return, dividends reinvested
1W
+2.5%
1M
+28.1%
YTD
+273.8%
1Y
+311.1%
From 52W high
−5.4%
From 52W low
+390.8%
$24
$125
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TWST stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Twist Bioscience Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
63 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
97
Quality
81
Revisions
63
Value
60
Accruals
60
Growth
51
Volatility
39
Issuance
29
Size
18

Momentum (97): The shares have been drifting up relative to others.

Issuance (29): The company has been issuing shares or taking on financing, diluting existing holders.

Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TWST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TWST, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120$140Oct 25Jan 26Apr 26Jul 26TWSTHigh $120Median $115Low $36

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
9 Buy2 Hold0 Sell
Low $36Median $115High $120

The green dot is the last close — the median target sits −3.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
5 Aug 2026Piper SandlerMaintainsOverweight$85 → $115
4 Aug 2026BairdMaintainsOutperform$113 → $115
14 July 2026Canaccord GenuityMaintainsBuy$90 → $120
14 July 2026Canaccord GenuityMaintainsBuy—
6 July 2026Evercore ISI GroupDowngradeIn-Line$66 → $102
6 July 2026Evercore ISI GroupDowngradeIn-Line—
29 June 2026GuggenheimMaintainsBuy$60 → $107
29 June 2026GuggenheimMaintainsBuy—
24 June 2026BarclaysMaintainsOverweight—
15 June 2026Canaccord GenuityInitiatesBuy—
15 June 2026TD CowenMaintainsBuy—
11 June 2026Piper SandlerInitiatesOverweight—
5 May 2026BairdMaintainsOutperform—
5 May 2026BarclaysMaintainsOverweight—
5 May 2026GuggenheimMaintainsBuy—
5 May 2026Leerink PartnersUpgradeOutperform—
14 Apr 2026BarclaysMaintainsOverweight—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
30 Mar 2026GuggenheimMaintainsBuy—
3 Feb 2026BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TWST appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TWST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Twist Bioscience Corp. (TWST) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−91.1×

Cheaper than 99% of US stocks

Price / sales
17.2×

Cheaper than 10% of US stocks

Price / book
16.7×

Cheaper than 6% of US stocks

EV / EBITDA
−64.0×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
23.2%

Higher than 73% of US stocks

Earnings growth (YoY)
23.2%

Higher than 62% of US stocks

Gross margin
52.8%

Higher than 66% of US stocks

Operating margin
−30.6%

Higher than 19% of US stocks

Net margin
−31.7%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−29.6%

Higher than 27% of US stocks

Return on assets
−13.1%

Higher than 24% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TWST vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
TWSTTwist Bioscience Corp.$7.4B
63
QGENQiagen NV$8.9B
62
RDNTRadNet, Inc.$5.9B
34
SHCSotera Health Co.$5.4B
95
ICLRIcon PLC$12.5B
67
RVTYRevvity, Inc.$13.0B
93
CRLCharles River Laboratories International, Inc.$13.8B
84

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Twist Bioscience Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TWST news & analysis

Alger Small Cap Growth Fund Q2 2026 Portfolio Review

Seeking Alpha · 14 Aug 2026positive

Alger Small Cap Growth Fund's Q2 2026 portfolio review reports that the Class A shares outperformed the Russell 2000 Growth Index during the quarter, with Twist Bioscience Corp. listed among the top contributors to fund performance.

Why it matters — A TWST watcher would care because the fund's review highlights Twist Bioscience as one of the strongest performers in its portfolio, signaling positive recognition from an institutional investor.

Artisan Global Discovery Fund Q2 2026 Portfolio Activity

Seeking Alpha · 6 Aug 2026neutral

Artisan Global Discovery Fund's Q2 2026 portfolio activity report details new positions in Entegris, Cellebrite and C.H. Robinson, additions to several holdings, and exits from ROBLOX, Colliers International and MongoDB. Twist Bioscience is not mentioned in the report.

Why it matters — A TWST watcher would care because the fund's portfolio activity does not reference Twist Bioscience, indicating no disclosed buying or selling of TWST shares during the quarter.

Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safety

Seeking Alpha · 5 Aug 2026positive

Twist Bioscience's stock has surged in 2026 due to improved growth prospects, driven by triple-digit AI-enabled drug discovery order growth, commercialization of oncology diagnostic assays, and expected margin improvements from operational efficiencies and higher-value products.

Why it matters — A TWST watcher would care because the article highlights strong momentum in AI drug discovery orders and diagnostic commercialization that could continue to shape the company's growth trajectory and margin profile.

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Business Wire · 5 Aug 2026neutral

Twist Bioscience Corporation announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price of $96.00 per share to the public. All shares in the offering are being sold by Twist, with gross proceeds to the company before underwriting discounts and commissions.

Why it matters — A Twist watcher would care because the offering raises capital for the company while increasing its outstanding share count.

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

Business Wire · 4 Aug 2026neutral

Twist Bioscience announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. The company intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares, with all offered shares being sold by Twist.

Why it matters — A TWST watcher would care because this proposed offering increases the number of common shares outstanding and raises new capital for the company, possibly affecting the share count investors track.

FAQ

Frequently asked questions about TWST stock

What is the TWST stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Twist Bioscience Corp. have a median 12-month price target of $115, with estimates ranging from $36 to $120. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TWST stock a buy right now?

Of the 11 analysts covering Twist Bioscience Corp., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Twist Bioscience Corp. 63 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TWST?

As at 15 Aug 2026, Twist Bioscience Corp. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will TWST stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies -3.0% from the last close, and Ticker Nerd's factor model ranks Twist Bioscience Corp. 63 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TWST stock forecast for 2030?

No analyst covering Twist Bioscience Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TWST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $120 over the next 12 months.

How has TWST stock performed over the past year?

Twist Bioscience Corp. returned +311.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Twist Bioscience Corp. do?

Twist Bioscience Corporation is a synthetic biology and biotechnology company that develops and commercializes DNA-based products built on its proprietary silicon-based synthesis platform. Twist Bioscience Corporation’s core offerings include synthetic genes, DNA oligos, oligo pools, library preparation tools, antibody libraries, and other workflow products used in next-generation sequencing, gene editing, drug discovery, diagnostics, and research.

What is the latest news on TWST?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "Alger Small Cap Growth Fund Q2 2026 Portfolio Review". Alger Small Cap Growth Fund's Q2 2026 portfolio review reports that the Class A shares outperformed the Russell 2000 Growth Index during the quarter, with Twist Bioscience Corp. listed among the top contributors to fund performance.

Company

About Twist Bioscience Corp.

Twist Bioscience Corporation is a synthetic biology and biotechnology company that develops and commercializes DNA-based products built on its proprietary silicon-based synthesis platform. Twist Bioscience Corporation’s core offerings include synthetic genes, DNA oligos, oligo pools, library preparation tools, antibody libraries, and other workflow products used in next-generation sequencing, gene editing, drug discovery, diagnostics, and research. The company serves customers across academic, pharmaceutical, biotech, industrial, and agricultural markets, providing scalable tools for applications that require precise, high-quality synthetic DNA. Its platform supports high-throughput manufacturing and a broad product portfolio that helps researchers and developers design, test, and advance biological innovation across multiple life science segments. Headquartered in South San Francisco, California, Twist Bioscience Corporation plays a specialized role in the global market for synthetic DNA and genomics-enabled research tools.

CEO Dr. Emily Marine Leproust Ph.D. · 979 employees · United States · https://www.twistbioscience.com